There's a lot of evidence that investors who focus on the long term, buying and holding stocks for many years, have the best shot at getting the best returns. We decided to take this concept to the extreme and asked four of our contributors to write about a stock they would never sell. They offered up an interesting mix of companies, including Mastercard Inc (NYSE: MA), iRobot Corporation (NASDAQ: IRBT), Allergan plc (NYSE: AGN), and Waste Management, Inc. (NYSE: WM).
These companies are very different from one another, but each offers a mix of durable advantages and long-term growth prospects. Does one of them belong in your "never sell" portfolio? Keep reading to find out.
A key player in a massive, long-term trend
According to a recent Pew Trusts
At the same time, technology is rapidly becoming more pervasive around the world, and few markets are set to benefit from this as much as electronic payments. As much as the card swipe (and increasingly, mobile payments) is commonplace in developed economies, they still make up a bare fraction of global financial transactions.
MasterCard is as well-positioned to benefit from these two massive trends as any company out there, as a global leader in an industry set to expand enormously in coming decades. That makes MasterCard an ideal "never sell" stock.
Clean up with this robot maker
But as it stands, one stock I wouldn't mind owning indefinitely (and have already owned for years) is iRobot Corporation, a home robot specialist best known for its popular Roomba robotic vacuums.
Of course, one obvious worry every shareholder should have is that of diversification. Even before iRobot
Outside of the Roomba, iRobot's affordable new Braava jet floor mopping robot is selling exceptionally well in overseas markets like Japan and China, where households predominantly have hardwood floors. And though iRobot already has a presence outside of the home, namely with its Mirra pool cleaning and Looj gutter cleaning robots, the company has also confirmed that it's in the early stages of developing a novel robotic lawn mowing solution, the introduction of which would
Considering iRobot's entire market capitalization as of this writing stands at just under $1.4 billion, I'll happily hold its stock as long as it takes to continue to watch its growth story unfold.
Despite the market's wrath, I'm sticking by this top pharma stock
Even so, I have no plans to sell this top pharma stock. In fact, I am using this extended period of weakness to add more shares because this stock looks to be grossly undervalued.
Turning to the specifics, Allergan's branded pharma portfolio sports several drugs with double-digit growth rates at the moment. In the third quarter, for example, sales of eye drop medication Restasis rose by 14% to $356.4 million, and the drugmaker's flagship cosmetic product, Botox, also saw its sales rise by 10% to $174.5 million, compared to the same period a year ago. The best part is that these kinds of stellar growth rates are fairly standard for Allergan's branded pharma business across the board.
Beyond its high-growth branded drug business, Allergan is also deeply committed to its shareholder rewards program. According to its Q3 earnings release, for instance, the drugmaker plans to plow an additional $10 billion into its accelerated share repurchase program, and initiate a quarterly dividend of $0.70 per share starting in the first quarter of 2017.
So, in light of Allergan's outstanding branded drug business and rich shareholder rewards, I'm more than happy to sit tight and simply let the moody market run its course.
Hardly worth throwing away
Waste Management takes all of those advantages and puts them in a tightly run ship that generates fantastic returns on capital for what is a relatively low-margin, low-growth industry. It also helps that management uses the cash generated from its high-return business to buy back stock and reward investors with a steadily growing dividend that yields a respectable 2.5%.
Perhaps if Wall Street were to lose its mind and push Waste Management's valuation into the stratosphere, I might consider selling this stock. Based on where it trades today, though, I'm more than happy to sit on this position while dividend checks come in and management increases my slice of the pie by retiring shares.
10 stocks we like better than MasterCard
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the
*Stock Advisor returns as of November 7, 2016